Phaseline

Targets › CAMK2A

CAMK2A (Calcium/calmodulin-dependent protein kinase type II subunit alpha): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Cardiovascular; next expected readout Apr 2027.

Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in various processes, such as synaptic plasticity, neurotransmitter release and long-term potentiation. Member of the NMDAR signaling complex in excitatory synapses, it regulates NMDAR-dependent potentiation of the AMPAR and therefore excitatory synaptic transmission (By…. (UniProt, Q9UQM7)

Open in Phaseline: the race on CAMK2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cardurion PharmaceuticalsCRD-4730
Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor
CAMK2A, CAMK2B, CAMK2D, CAMK2GPhase 2Catecholaminergic Polymorphic Ventricular Tachycardia; Heart Failure With Reduced Ejection Fraction (HFrEF)Apr 2027

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1)

Modalities

small molecule (1)

Companies

Cardurion Pharmaceuticals (1)

Related targets

CAMK2B (1) CAMK2D (1) CAMK2G (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.